Thursday, 8th June 2017
THIS EVENT IS CPD CERTIFIED
This seminar will provide the opportunity to discuss the future of biosimilar medicines in the UK.
Delegates will assess the next steps for regulation and pharmacovigilance, the impact of increased competition between originator and biosimilar manufacturers and the challenges for embedding use in service delivery following the publication of NHS England’s ‘What is a biosimilar medicine?’ guide.
Sessions will also focus on the implications of the UK vote to leave the European Union on access to biosimilars, key issues for clinicians around switching from originator to biosimilar - and the next steps for patient engagement, education and involvement.